| 1. Fabrizio P, Pozza F, Pletcher SD, Gendron CM, Longo VD. (2001) Regulation of longevity and stress resistance by Sch9 in yeast.. Science, 292 (5515): (288-90). [PMID:11292860] |
| 2. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.. Curr Biol, 14 (14): (1296-302). [PMID:15268862] |
| 3. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS et al.. (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.. Nature, 460 (7253): (392-5). [PMID:19587680] |
| 4. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P et al.. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.. Cancer Res, 70 (1): (288-98). [PMID:20028854] |
| 5. Yang Z, Klionsky DJ. (2010) Mammalian autophagy: core molecular machinery and signaling regulation.. Curr Opin Cell Biol, 22 (2): (124-31). [PMID:20034776] |
| 6. Robida-Stubbs S, Glover-Cutter K, Lamming DW, Mizunuma M, Narasimhan SD, Neumann-Haefelin E, Sabatini DM, Blackwell TK. (2012) TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO.. Cell Metab, 15 (5): (713-24). [PMID:22560223] |
| 7. Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, Martin NM, Ruston L, Pass SL, Pass M. (2013) Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.. Bioorg Med Chem Lett, 23 (5): (1212-6). [PMID:23375793] |
| 8. Datan E, Shirazian A, Benjamin S, Matassov D, Tinari A, Malorni W, Lockshin RA, Garcia-Sastre A, Zakeri Z. (2014) mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection.. Virology, 452-453 (3): (175-90). [PMID:24606695] |
| 9. Dittmar M, Lee JS, Whig K, Segrist E, Li M, Kamalia B, Castellana L, Ayyanathan K, Cardenas-Diaz FL, Morrisey EE et al.. (2021) Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2.. Cell Rep, 129 (3): (108959). [PMID:33811811] |
C2215150